Panacea Biotec Limited
Our verdict
Valuation (70/100) does the heavy lifting; momentum (6/100) is the drag.
Our fair value
Undervalued by 73%Buy-below (20% margin of safety): ₹488.95
TickerMagic rates Panacea Biotec Limited a Sell, scoring 37/100 on our blended model. The price is about 42% below its 52-week high of ₹607.75 and 19% above the low of ₹296.05. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 4 of 11 investability checks, with durability 34, valuation 39 and momentum 6 on our 0–100 scales.
Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹488.95. Low-confidence estimate — limited data.
1-year price
EOD · 2026-11-2052-week range
-41.94% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell37Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.03x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 1%
- Fail: Earnings growing: -12%
- Fail: Net margin ≥ 10%: -1.3%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.3
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter72.7%
- Institutions0.1%
- Public & other27.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 6.3.
Opportunities
- Well off its 52-week high — possible mean-reversion.
- Trades ~73% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (2/9).
Threats
- Earnings contracting year on year.
About Panacea Biotec Limited
Panacea Biotec Limited develops and manufactures vaccines, pharmaceuticals, nutraceuticals, and nutrition products for domestic and international markets. Operating through vaccines and pharmaceutical formulations & nutrition divisions, the company offers prescription products across oncology, diabetes, gastro-intestinal care, nephrology, and orthopedic therapeutic areas.
Panacea Biotec Limited — frequently asked questions
Is Panacea Biotec Limited a buy, hold or sell?
TickerMagic currently rates Panacea Biotec Limited (PANACEABIO) a Sell, based on a blended score of 37/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Panacea Biotec Limited's fair value?
Our blended DCF and relative-valuation model estimates Panacea Biotec Limited's fair value at about ₹611.18, versus a current price of ₹352.85 — roughly 73% upside. On that basis the stock looks undervalued by 73%.
Is Panacea Biotec Limited financially healthy?
Panacea Biotec Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Panacea Biotec Limited's share price performed?
Panacea Biotec Limited is down 13% over three months, and last traded at ₹352.85. Past performance doesn't predict future returns.
More in Healthcare
Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.